Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) on November 15 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback